NurExone Biologic

Company Overview

Snapshot

Founded in January 2020, NurExone Biologic operates with 11–50 employees and has raised a total of $9.53M across 8 funding rounds. The company went public on the TSXV in July 2022.

Business overview

NurExone Biologic is a Health Tech & Life Sciences company focused on revolutionizing recovery from central nervous system injuries. The company is developing a biological extracellular vesicles-based drug platform designed to regenerate and rewire neurons. Its novel approach to spinal cord injury (SCI) treatment utilizes intranasal exosome administration, offering an alternative to existing therapies. NurExone operates within the Drugs Discovery & Development sector, targeting the Pharmaceuticals market with its exosome-based therapies.

Strategic signal

In September 2025, NurExone Biologic received a U.S. patent allowance for its exosome manufacturing process, which strengthens its supply chain readiness. This development signals to investors a significant step towards commercialization and scaling production of its EV-based drug platform, enhancing the company's position in the regenerative medicine market.

Company Intelligence Q&A

What was a key regulatory milestone achieved by NurExone Biologic in October 2023?

In October 2023, NurExone Biologic received FDA Orphan-Drug Designation for its ExoPTEN therapy, accelerating its development for acute spinal cord injury treatment.

What strategic move did NurExone Biologic make in November 2024 to expand its market reach?

In November 2024, NurExone Biologic secured EMA Orphan Status for ExoPTEN in Spinal Cord Injury, which is expected to accelerate its pathway to European markets.

What significant preclinical data did NurExone Biologic present in May 2025?

In May 2025, NurExone Biologic advanced its vision restoration strategy by presenting preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) 2025.

What manufacturing and supply chain development did NurExone Biologic announce in September 2025?

In September 2025, NurExone Biologic received a U.S. patent allowance for exosome manufacturing, strengthening its supply chain readiness.

What strategic partnership did NurExone Biologic secure in October 2023?

In October 2023, NurExone Biologic secured a Eureka Grant for a collaborative partnership aimed at expanding its spinal cord injury therapy to chronic conditions.